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Short report Markers of inflammation and coagulation indicate 
a prothrombotic state in HIV-infected patients with 
long-term use of antiretroviral therapy with or 
without abacavir
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Abstract
Background: Abacavir (ABC) treatment has been associated with an increased incidence of myocardial infarction. The 
pathophysiological mechanism is unknown. In this study markers of inflammation and coagulation in HIV-infected 
patients using antiretroviral therapy with or without ABC were examined to pinpoint a pathogenic mechanism. Given 
the important role of high sensitivity C-reactive protein (hsCRP) levels in predicting cardiovascular risk, patient groups 
were also analyzed according to hsCRP levels.
Methods: Patients treated with ABC and a matched control group treated without ABC were selected retrospectively. 
Vascular endothelial growth factor (VEGF) and markers of endothelial cell activation (von Willebrand factor (vWF), factor 
VIII), fibrin formation (fibrinogen, D-dimer, prothrombin fragment 1+2 (F1+2), endogenous thrombin potential (ETP)), 
anticoagulation markers (protein C and S, activated protein C sensitivity ratio (APCsr)) and inflammation markers (IL-6, 
hsCRP) were measured in citrated plasma.
Results: A total of 81 patients were included of whom 27 patients used an ABC-containing regimen and 54 used a 
non-ABC-containing regimen. Patient characteristics were not significantly different between the groups except for 
longer duration of use of the current antiretroviral regimen in the ABC group (p = 0.01). The median time on ABC was 
68 months (interquartile range 59-80 months). No differences in coagulation and inflammation markers according to 
ABC use were observed. For the whole patient group elevated vWF and F1+2 levels were observed in 23% and 37%, 
respectively. Compared to the reference ranges for the general population increased APCsr was found in 79% and 
lower protein C and VEGF levels in 40% and 43%, respectively. Patients in the high-risk category for cardiovascular 
disease with hsCRP levels > 3 mg/L had significantly higher fibrinogen, D-dimer, F1+2 and ETP levels compared to 
patients from the low-risk category with hsCRP levels < 1 mg/L.
Conclusion: HIV-infected patients using ABC showed no specific abnormalities in coagulation or inflammation 
markers that might explain the increased risk of myocardial infarction. For the whole group, regardless of ABC use, 
evidence of a prothrombotic state was observed. Thirty-three percent of patients with long-term use of antiretroviral 
treatment had hsCRP levels above 3 mg/L, which is strongly associated with cardiovascular disease in HIV-uninfected 
individuals.
Background
The Data Collection on Adverse Events of Anti-HIV
Drugs (D:A:D) study, an observational study in over
30.000 HIV-1 infected individuals, reported an increased
risk of myocardial infarction in HIV-infected patients
with current or recent exposure to abacavir (ABC) and
didanosine (ddI)[1]. The SMART study and a Danish
study by Obel et al. observed a similar association with
severe cardiovascular disease [2,3]. The increased risk
was evident while patients were actually receiving the
drugs up to 6 months after stopping them. However, the
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ACTG study group and GlaxoSmithKline-sponsored
clinical trials observed no association between ABC use
and increased risk of myocardial infarction or severe car-
diovascular disease [4,5]. As possible pathogenic mecha-
nisms endothelial dysfunction, a proinflammatory state
with plaque rupture and subsequent thrombosis and
platelet hyperreactivity have been suggested [6-9]. Earlier
studies focussed on markers of inflammation and coagu-
lation before and after initiation of an ABC-containing
regimen. No changes in high sensitivity C-reactive pro-
tein (hsCRP), interleukin (IL)-6, soluble vascular adhe-
sion molecule and D-dimer levels were observed [8,9]. In
a recent study increases in metallopeptidase 9, myeloper-
oxidase and hsCRP levels as markers of cardiovascular
risk were observed in a longitudinal cohort of virologi-
cally suppressed patients switching to ABC[10]. Earlier
studies in non-HIV infected individuals described ele-
vated high sensitivity C-reactive protein (hsCRP) levels as
the most important factor in predicting cardiovascular
risk [11]. Hsue et al. demonstrated lower flow-mediated
vasodilatation as marker of endothelial dysfunction in
patients on ABC [6]. Vascular endothelial growth factor
(VEGF) could be an inducible factor in the process of
endothelial dysfunction, but has not been studied in this
setting. Anti-angiogenic properties through an inhibitory
effect on VEGF were attributed to protease inhibitors in
glioblastoma cells and treatment of Kaposi sarcoma
[12,13]. Inhibition of VEGF was associated with throm-
botic microangiopathy of the kidney [14].
Table 1: Patient characteristics according to ABC use
ABC-containing regimen Non-ABC-containing regimen
Number of patients (% male) 27 (89) 54 (89)
Age (years) 48 ± 11 47 ± 10
Ethnicity
Caucasian (%) 23 (85) 43 (80)
African-American (%) 1 (4) 4 (7)
Asian (%) 2 (7) 4 (7)
Other (%) 1 (4) 3 (6)
Current smoker (%) 13 (48) 19 (35)
Chronic hepatitis C infection (%) 2 (7) 4 (7)
Chronic hepatitis B infection (%) 1 (4) 1 (2)
History of cardiovascular event (%) 1 (4) -
Total duration of cART use (months) 116 (85-129)* 91 (33-121)
Total time on ABC (months) 68 (59-80) -
cART regimen
ABC + other NRTI (%) 11 (41) -
ABC + PI (%) 7 (26) -
ABC + NNRTI (%) 9 (33) -
non-ABC + PI (%) - 27 (50)
non-ABC + NNRTI (%) - 27 (50)
CD4 cell count (cells/mm3) 490 (310-770) 530 (300-720)
HIV viral load <40 copies/ml (%) 23 (85) 46 (85)
Duration HIV viral load <40 copies/ml 
(months)
90 (72-113) 68 (22-120)
Total cholesterol (mmol/L) 5.0 ± 0.9 5.0 ± 1.0
Triglycerides (mmol/L) 2.5 ± 1.9 2.2 ± 1.7
Non-fasting glucose (mmol/L) 6.1 ± 1.2 5.9 ± 1.5
Use of antihypertensive drugs (%) 2 (7) 7 (13)
Use of statins (%) 7 (26) 6 (11)
Use of oral antidiabetics (%) 1 (4) 0 (-)
cART = combined antiretroviral therapy; ABC = abacavir; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse 
transcriptase inhibitor; PI = protease inhibitor
* p < 0.05Jong et al. AIDS Research and Therapy 2010, 7:9
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In the current study markers of inflammation and coag-
ulation in HIV-infected patients on present combined
antiretroviral therapy (cART) with or without ABC were
compared in order to pinpoint a pathogenic mechanism
for the increased risk of myocardial infarction in patients
using ABC. Given the important role of hsCRP levels in
predicting cardiovascular risk, patient groups were also
analyzed according to hsCRP levels.
Methods
Study population
All patients using an ABC-containing regimen were ret-
rospectively selected from the Slotervaart HIV cohort
study, a prospective cohort study on markers of coagula-
tion and inflammation in HIV-infected patients. The
control group existed of HIV-infected patients participat-
ing in the Slotervaart HIV cohort study who were using
cART without ABC including a protease inhibitor (PI) or
a non-nucleoside transcriptase inhibitor (NNRTI) and
were matched for age, sex, CD4 cell count and HIV viral
load. Patients using ddI were excluded. Blood was taken
at a follow-up visit in the outpatient clinic, when the
patient showed no signs of active infection.
Laboratory testing
PT, aPTT and markers of endothelial cell activation (von
Willebrand factor (vWF), VEGF)), fibrin formation
(fibrinogen, D-dimer, prothrombin fragment 1+ 2 (F1+2),
endogenous thrombin potential (ETP)), anticoagulation
(protein C and S, activated protein C sensitivity ratio
(APCsr)) and inflammation (IL-6, hsCRP) were measured
in citrated plasma as described before[15] VEGF, hsCRP
and IL-6 were assayed by ELISA (R&D Systems Europe
Ltd., Abingdon, UK). The ETP assay is a global coagula-
tion assay that measures thrombin generation in tissue
factor triggered platelet-poor plasma, providing an esti-
mation of the potential to form a clot under (patho)physi-
ological conditions. The ETP was determined with a
Calibrated Automated Thrombogram (CAT). The CAT
assays the generation of thrombin in clotting plasma
using a microtiter plate reading fluorometer (Fluoroskan
Ascent, ThermoLab systems, Helsinki, Finland) and
Thrombinoscope software (Thrombinoscope BV, Maas-
tricht, the Netherlands) as previously described [16].
CD4 cell counts were analyzed using flow cytometric
techniques (Becton Dickinson, USA). HIV RNA levels
were quantified using the COBAS Ampliprep and
COBAS TaqMan (Roche Diagnostics, Almere, The Neth-
erlands).
Statistical methods
Continuous variables were expressed as median values
(interquartile range (IQR)) for not normally distributed
variables and means (standard deviation) for normally
Table 2: Results of laboratory parameters according to ABC use*
Laboratory parameter ABC-containing regimen (n = 27) Non-ABC-containing regimen (n = 54) Reference range for 
the general population
aPTT (sec) 30.8 (29.5-33.9) 31.4 (29.4-33.7) 25.0-38.0
PT (sec) 11.5 (11.0-12.0) 11.7 (11.1-12.2) 10.7-12.9
Fibrinogen (g/L) 2.9 (2.5-3.2) 2.7 (2.3-3.5) 1.9-4.0
FVIII (%) 119 (103-175) 119 (100-144) 63-173
vWF (%) 112 (89-185) 124 (100-168) 50-150
D-dimer (mg/L) 0.4 (0.2-0.4) 0.2 (0.2-0.4) <1.00
F1+2 (pmol/L) 213 (177-276) 196 (122-257) 53-271
PC (%) 115 (98-138) 116 (98-127) 70-120
PS total (%) 105 (90-115) 104 (86-114) 58-130
PS free (%) 81 (68-102) 82 (70-99) 63-137
ETP (nM.min) 1844 (1620-2052) 1740 (1602-1959) 1155-2606
ETP peak (nM) 381 (345-394) 374 (339-414) 194-503
APCsr 2.2 (1.7-4.0) 2.5 (1.9-3.3) <1.6
VEGF (pg/ml) 37 (27-47) 33 (23-51) 31-86
IL-6 (pg/ml) <1.0 (-) <1.0 (-) <4.0
hsCRP (mg/L) 1.6 (0.4-5.3) 1.6 (0.5-3.3) <1.0
*The results are shown as median values (interquartile range)
ABC = abacavir; fVIII = factor VIII; vWF = von Willebrand factor; F1+2 = prothrombin fragment 1+2; PC = protein C; PS = protein S; ETP = 
endogenous thrombin potential; APCsr = activated protein C sensitivity ratio; VEGF = vascular endothelial growth factor; hsCPR = high-
sensitivity C-reactive proteinJong et al. AIDS Research and Therapy 2010, 7:9
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distributed variables. Categorical variables were
expressed as counts and percentages. Coagulation and
inflammation markers were compared between patient
groups with and without ABC. Besides, all patients were
stratified in low-risk, average-risk and high-risk catego-
ries for cardiovascular disease according to their hsCRP
levels independent of ABC use. hsCRP levels of <1.0 mg/
L indicated low-risk, hsCRP levels of 1.0 - 3.0 mg/L indi-
cated average-risk and hsCRP levels > 3.0 mg/L indicated
high-risk for cardiovascular disease [11]. Normally dis-
tributed parameters were compared using a two-sample
independent t-test. For not normally distributed parame-
ters a Mann-Whitney test was used. Dichotomous vari-
ables were compared using a Chi-squared test.
Categorical variables were analyzed using a Kruskall Wal-
lis test with Bonferroni correction for multiple testing. A
p-value of < .05 was considered significant. The calcula-
tions were performed using the Statistical Package for
Social Sciences (SPSS Inc., Chicago, Illinois, version 16.0)
software package.
Results
A total of 81 patients were identified with a median age of
47 years (26-73 years), of whom 89% were male and 82%
Caucasian. Twenty-seven patients were using an ABC-
containing regimen and 54 a non-ABC-containing regi-
men. In both treatment groups 85% of patients were viro-
logically suppressed for many years. One patient had a
history of an ischemic cerebrovascular accident while on
ABC before inclusion in the study. No patients with a
documented myocardial infarction were reported. The
patient characteristics stratified according to use of ABC
are shown in Table 1. There were no significant differ-
ences between the groups except for longer duration of
cART use in the patients treated with ABC (p = 0.01).
The median time on ABC was 68 months (IQR 59-80
months).
The median (IQR) of the laboratory markers according
to ABC use are shown in Table 2. Table 3 shows the per-
centage of patients with a test result outside the reference
range. No significant differences in laboratory parameters
were observed between patients treated with and without
Table 3: Number (%) of patients with laboratory parameters outside the reference range
Laboratory parameter Total group (n = 81) ABC-containing regimen (n = 27) Non-ABC-containing regimen (n = 54)
Prolonged aPTT 2 (3) 0 (-) 2 (4)
Prolonged PT 5 (6) 1 (4) 4 (7)
Elevated fibrinogen 11 (14) 3 (11) 6 (11)
Elevated FVIII 14 (17) 6 (22) 8 (15)
Elevated vWF 19 (23) 7 (26) 12 (22)
Elevated D-dimer 3 (4) 2 (7) 1 (2)
Elevated F1+2 30 (37) 10 (37) 20 (37)
Decreased PC 32 (40) 11 (41) 21 (39)
Decreased total protein S 6 (7) 3 (11) 3 (6)
Decreased free protein S 11 (14) 4 (15) 7 (13)
Increased ETP 0 (-) 0 (-) 0 (-)
Increased peak ETP 2 (3) 0 (-) 2 (4)
Increased APCsr 64 (79) 21 (78) 43 (80)
Decreased VEGF 4 (5) 2 (7) 2 (4)
Elevated IL-6 35 (43) 10 (37) 25 (46)
hsCRP category
Low risk (hsCRP < 1 mg/L) 28 (35) 9 (33) 19 (35)
Average risk (hsCRP 1-3 
mg/L)
24 (30) 6 (22) 18 (33)
High risk (hsCRP >3 mg/L) 27 (33) 10 (37) 17 (32)
Missing 2 (3) 2 (7) -
ABC = abacavir; fVIII = factor VIII; vWF = von Willebrand factor; F1+2 = prothrombin fragment 1+2; PC = protein C; PS = protein S; ETP = 
endogenous thrombin potential; APCsr = activated protein C sensitivity ratio; VEGF = vascular endothelial growth factor; hsCRP = high-
sensitivity C-reactive proteinJong et al. AIDS Research and Therapy 2010, 7:9
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ABC. However, for the whole group, we found elevated
vWF levels in 23% of patients, elevated F1+2 levels in 37%
of patients, while APCsr was increased in 79% of patients
compared to the reference ranges for the general popula-
tion. Low PC levels were observed in 40% and decreased
VEGF levels in 43% of patients. IL-6 levels were low for
the whole group. When stratified into risk categories for
cardiovascular disease according to hsCRP levels, 28
(35%) patients fell in the low-risk category, 24 (30%) in
the average-risk category and 27 (33%) in the high-risk
category for cardiovascular disease. Patients on ABC
were evenly distributed between the various categories.
In Table 4 mean and median values for demographic and
laboratory parameters are depicted grouped by risk cate-
gory. Significantly higher fibrinogen, D-dimer, F1+2 and
ETP levels were observed when the high-risk category
was compared to the low-risk category. When only
patients using ABC were selected this finding was con-
firmed for fibrinogen and D-dimer levels.
Discussion
We studied markers of inflammation and coagulation in
HIV-infected patients treated with and without ABC to
pinpoint a pathogenic mechanism for the increased risk
of myocardial infarction in patients with current or
recent (up to 6 months) exposure to ABC. Previous stud-
ies primarily focussed on markers of coagulation and
inflammation before and after initiation of an ABC-con-
taining regimen. In these studies changes in hsCRP, IL-6,
soluble vascular adhesion molecule and D-dimer levels
were not significantly different between patient groups
treated with or without ABC [8,9]. We focussed on HIV-
infected patients with long-term use of cART. Our find-
ings showed no differences in inflammation and coagula-
Table 4: Demographic and laboratory parameters stratified to risk category based on hsCRP levels
Low risk category 





Number of patients 28 24 27
Age (years) 47.8 (± 10.2) 48.4 (± 11.6) 48.2 (± 9.1)
Duration of cART use (months) 76 (25-125) 116 (42-124) 111 (26-127)
CD4 cell count (cells/mm3) 390 (300-765) 460 (340-805) 500 (288-633)
HIV viral load <40 copies/ml (%) 24 (86) 21 (88) 22 (81)
Total cholesterol (mmol/L) 4.9 (± 1.0) 5.7 (± 0.9) 5.1 (± 0.8)
Triglycerides (mmol/L) 2.2 (± 1.9) 2.7 (± 2.0) 2.0 (± 1.4)
Non-fasting glucose (mmol/L) 5.9 (± 1.1) 5.9 (± 1.1) 6.1 (± 1.6)
Patients on ABC (%) 9 (32) 7 (29) 11 (41)
aPTT (sec) 31.5 (± 3.3) 32.2 (± 3.1) 30.5 (± 3.2)
PT (sec) 11.8 (± 0.9) 11.7 (± 0.6) 11.5 (± 0.8)
Fibrinogen (g/L) 2.4 (2.1-2.6) 2.8 (2.3-3.2)* 3.5 (2.8-4.1)*
FVIII (%) 115 (102-145) 122 (105-172) 122 (100-158)
vWF (%) 124 (92-160) 123 (101-177) 114 (98-188)
D-dimer (mg/L) 0.2 (0.2-0.3) 0.2 (0.2-0.3) 0.3 (0.2-0.5)*
F1+2 (pmol/L) 175 (151-229) 210 (163-269) 219 (197-305)*
PC (%) 114 (± 25.7) 111 (± 20.6) 120 (± 20.9)
PS total (%) 96 (± 18.7) 104 (± 14.5) 105 (± 20.8)
PS free (%) 87 (± 16.8) 93 (± 24.8) 82 (± 26.0)
ETP (nM.min) 1663 (± 274) 1803 (± 237)* 1913 (± 336)*
ETP peak (nM) 371 (328-401) 371 (341-407) 386 (364-417)
APCsr 2.9 (2.1-3.7) 2.0 (1.7-2.9)* 2.6 (1.6-4.4)
VEGF (pg/ml) 30 (24-42) 30 (26-52) 37 (27-53)
IL-6 (pg/ml) 1.0 (-) 1.0 (-) 1.0 (-)
hsCRP = high-sensitivity C-reactive protein; fVIII = factor; vWF = von Willebrand factor; F1+2 = prothrombin fragment 1+2; PC = protein C; PS 
= protein S; ETP = endogenous thrombin potential; APCsr = activated protein C sensitivity ratio; VEGF = vascular endothelial growth factor
*p < 0.05 (after Bonferroni correction for multiple testing)Jong et al. AIDS Research and Therapy 2010, 7:9
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tion markers between HIV-infected patients treated with
long-term cART with or without ABC.
In the current study, we hypothesized that VEGF, an
important factor in the repair system of endothelial
injury, might play a pathogenic role. VEGF is associated
with angiogenesis, chemotaxis of macrophages and gran-
ulocytes, and vasodilatation. Anti-angiogenic properties
through an inhibitory effect on VEGF were attributed to
PIs in glioblastoma cells and treatment of Kaposi sarcoma
[12,13]. No differences in VEGF levels were observed
between patients on an ABC-containing regimen or a
non-ABC-containing regimen. Nevertheless, VEGF levels
were reduced in a significant proportion of the whole
group of HIV-infected patients with long-term use of
cART. This might be suggestive of a decrease in angio-
genesis and endothelial repair. Use of PIs was evenly dis-
tributed between the two groups. No difference in VEGF
levels was observed between patients using PIs or
NNRTIs.
For the whole group evidence of endothelial cell activa-
tion, increased fibrin formation and decreased anticoagu-
lation was observed compatible with a prothrombotic
state. Furthermore, 33% of the patients with long term
use of cART with undetectable or very low levels of viral
replication had hsCRP levels >3 mg/L, which are strongly
linked to cardiovascular disease in HIV-uninfected indi-
viduals [11]. IL-6 levels were low for the whole group
indicating low levels of inflammation. A trend was
observed of higher hsCRP levels in both the ABC- and
non-ABC group with longer duration of cART use. Ear-
lier Pallela et al. reported an increase in hsCRP levels
between baseline and index visits (mean 4.2 years apart)
in HIV-infected women on cART with or without ABC
[9]. Higher hsCRP levels in HIV-infected individuals were
also reported by Hsue et al. when comparing HIV-
infected individuals to the general population [17]. In our
study the high-risk category with hsCRP levels >3 mg/L
showed increased fibrinogen, D-dimer, F1+2 and ETP
levels indicating a prothrombotic state. No differences in
markers of endothelial cell activation or anticoagulation
according to hsCRP levels were observed.
The significant difference in duration of cART use
could be a limitation of the study. If as hypothesized, ABC
use would be associated with abnormal inflammation and
coagulation markers this would probably be accentuated
by longer duration of ABC use. Actually, no differences
were observed between the two study groups. Further-
more, by using a cross-sectional design no conclusions
could be drawn regarding the association of the observed
inflammation and coagulation abnormalities and cardio-
vascular events.
Conclusion
HIV-infected patients using ABC showed no specific
abnormalities in coagulation or inflammation markers
that might explain the increased risk of myocardial
infarction. For the whole patient group, regardless of
ABC use, evidence of a prothrombotic state was
observed. Thirty-three percent of patients with long-
term use of cART and undetectable viral load, had hsCRP
levels above 3 mg/L, which is strongly associated with
cardiovascular disease in HIV-uninfected individuals.
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